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HormoneThe aim was to analyze the effect of leukotriene synthesis inhibitor administered intraperitoneally in
vasopressin release during sepsis. Male Wistar rats received injections of MK-886 (1.0, 2.0 or 4.0 mg/kg) or
vehicle (DMSO 5%) 1 h before cecal ligation and puncture. There was some variation on the survival rate
depending on the dose used but the drug did not modify the hematocrit, osmolality, serum sodium and
nitrate, plasma protein, and neutrophil recruitment, in any dose. Nevertheless, vasopressin (AVP) release
decreased in a dose–response manner in the early phase of sepsis. These results support the suggestion that
leukotrienes (LTs) are involved in AVP release during sepsis.: +55 16 3633 0999.
.
vier OA license.© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Clinical and experimental studies report that in the initial phase of
sepsis, high AVP levels can be found in plasma of patients or animals.
This can be interpreted as a systemic attempt, to restore bloodpressure
that tends to decrease due to cytokines and NO release. Notwith-
standing, in the late phase, when the observed hypotension would be
expected to stimulate AVP secretion, its plasma levels were inappro-
priately low (Landry et al., 1997; Landry and Oliver, 2001; Sharshar
et al., 2003). Low plasma AVP levels can be considered a deleterious
consequence of an abnormal pituitary response due to baroreﬂex
impairment and high levels of nitric oxide that will also contribute to
the hypotension, progression of sepsis, multiple organ failure and
death (Landry et al., 1997; Holmes et al., 2001; Sharshar et al., 2003;
Maxime et al., 2007). Understanding in detail the mechanisms
responsible for the release of this hormone during sepsis should,
thus, be of clinical importance.
During sepsis, proinﬂammatory cytokines are released in an
uncontrolled manner, and a large number of these, in particular
tumor necrosis factor (TNF)-α, interleukin (IL)-1α and interferon
(IFN)-γ, as well as nitric oxide (NO), have been implicated in the
pathophysiological process of this disease (Rios-Santos et al., 2003;Benjamim et al., 2005; Sriskandan and Altmann, 2008). At present, a
growing body of evidence suggests that also lipid-derived inﬂamma-
tory mediators, such as leukotrienes (LTs), may play a key role in
sepsis-associated disorders (Sprague et al., 1989; Morlion et al., 2000;
Benjamim et al., 2005; Baenkler et al., 2006). The capacity for
complete biosynthesis of LTs from arachidonic acid (AA) is largely
conﬁned to leukocytes, and the biosynthesis pathway can be triggered
by a variety of stimuli, including lipopolysaccharide (LPS), IL-1 and
TNF-α. These stimuli activate signal transduction cascades that, in
turn, activate LTs-forming enzymes (Clark et al., 1995; Hirabayashi
and Shimizu, 2000). Brieﬂy, a cytosolic phospholipase A2 (cPLA2)
initiates the synthesis of LTs by cleavage of AA from membrane
phospholipids. The subsequent interaction of AA with 5-lipoxygenase
(5-LO) and 5-lipoxygenase activating protein (FLAP) forms the interme-
diate 5-HPETE (5-hydroxyperoxy-6,8,11,14-eicosatetraenoic acid),which
is rapidly converted to LTA4. This unstable intermediate can be
hydrolyzed to form LTB4 or it can be conjugated with glutathione by
LTC4 synthase to produce the cysteinyl leukotrienes (cys-LTs) LTC4, LTD4
and LTE4 (Peters-Golden and Brock, 2003; Peters-Golden andHenderson,
2007). Furthermore, LTA4 generated in one cell can be taken up by
another one that expresses LTA4 hydrolase or LTC4 synthase to there
continue its biochemical transformation (Murphy and Gijon, 2007). This
process named transcellular biosynthesis suggests that the cellular
environment exerts an important control over LTs production (Di
Gennaro et al., 2004). In functional terms, LTB4 promotes chemotaxis,
activation and adhesion of leukocytes to endothelial cells, thus being the
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infection locus (Cunningham et al., 1980; Ford-Hutchinson et al., 1980;
Gimbrone et al., 1984; Flamand et al., 2007). In contrast, the cys-LTs are
better known for their bronchoconstriction effects, characteristic symp-
toms of patients with asthma (Dahlen et al., 1980), and in blood vessels
they increase vascular permeability and cause hypotension (Dahlen et al.,
1980; Smedegard et al., 1982; Henderson and Klebanoff, 1983; Goulet
et al., 2000; Flamand et al., 2007). Cys-LTs are also involved in a complex
network of interactionswith a variety of inﬂammatorymediators, such as
NO. Several studies have demonstrated the effect of inhibitors or
antagonists of LTs in NO production. Montelukast (antagonist of Cys-
LT1 receptor) has been shown to reduce levels of exhaled NO in clinical
trialswith asthmatic adults (Wilson et al., 2001; Sandrini et al., 2003) and
children (Bisgaard et al., 1999; Bratton et al., 1999). This antagonist was
also shown to reduce the expression of iNOS in the lung of rats (Knigge
et al., 2003). In glial cells, the MK-886 (an LT biosynthesis inhibitor) was
responsible for reducing the LPS-induced iNOS expression and NO
production, suggesting that 5-LO mediates iNOS gene expression during
endotoxemia (Won et al., 2005).
A growing body of evidence suggests that LTs also play an important
role in the central nervous system (Lindgren et al., 1985; Shimada et al.,
2005) due to the expression of 5-LO and FLAP protein (Lammers et al.,
1996), as well as the expression of CysLT2 (cys-LT receptor) in several
brain regions, including the hypothalamus (Heise et al., 2000). One of
the ﬁrst reports describing a biological effect of LTs in the brain involved
the neuroendocrine system. In vitro studies showed that the release of
luteinizing hormone (LH) from pituitary cells in response to gonado-
trophins releasing hormone (GnRH) was partly mediated by LTs. The
response appears to be LTC4 speciﬁc since LTB4 did not alter the release
of LH (Hulting et al., 1985). In the brain, LTC4 also seems to be related
with the vasopressinergic system of the hypothalamic–neurohypophy-
seal axis. LTC4 synthase, butnot LTA4hydrolase,was selectively localized
in vasopressinergic neurons of the hypothalamic paraventricular,
supraoptic and suprachiasmatic nuclei and in the retrochiasmatic area.
In addition it was detected in axons emanating from these neurons to
the neurohypophysis (Shimada et al., 2005).
In a recent study from our laboratory we suggested that LTs are
involved in arginine vasopressin (AVP) release. The central adminis-
tration of an inhibitor of leukotriene synthesis in rat abolished the
secretion of AVP in the initial phase of the sepsis. Furthermore, its
injection improved survival and attenuated the increase of LTC4
enzyme in the hypothalamus and of serum nitrate levels seen during
sepsis (Athayde et al., 2009). As already shown, NOS inhibitor may
also affect vasopressin secretion during sepsis, though the results
depend on the route of inhibitor administration (Carnio et al., 2006;
Corrêa et al., 2007). The objective of this work was to investigate the
effects of an intraperitonially administered inhibitor of leukotriene
synthesis on AVP release and NO production in the course of experi-
mental sepsis.2. Material and methods
2.1. Animals
Male Wistar rats (250±30 g) from the Animal Care Facility of the
Universidade de São Paulo (USP), Campus Ribeirão Preto were used in
the present study. The rats were housed in controlled temperature
(25±1 °C) and photoperiod (12-h light/dark cycle) conditions, with
food (Nuvilab CR-1, Nuvital Nutrientes, Paraná, Brazil) and water
available ad libitum. All experimental protocols were performed
according to the international guidelines on the ethical use of animals
and approved by the Animal Ethics Committee of USP (CEUA)-
Campus Ribeirão Preto, deﬁning the number of animals used and
minimizing their suffering. Humane endpoints in shock research
(Nemzek et al., 2004) were used as criteria to euthanize CLP animalsin high suffering immediately before or soon after the time-points
deﬁned in this study.
2.2. Experimental protocol
The animals received an intraperitoneal (i.p.) injection of 1 ml
containing dimethyl sulfoxide (DMSO) 5% as vehicle or an inhibitor of
leukotriene synthesis, MK-886 (3-[1-(p-chlorobenzyl)-5-(isopropyl)-
3-tert-butylthioindol-2-yl]-2,2-dimethylpropanoic acid, Merck Frosst
Canada Ltd., Quebec, Canada) 1 h before CLP or sham operation. The
biological half life of MK-886 is reported to be 2 h (Friedman et al.,
1993). In the ﬁrst group of animals (n=80), the survival of the
animals was monitored for 3 days. In the second group (n=200) the
animals were decapitated at 0, 4 (early phase of sepsis) or 24 h (late
phase of sepsis) after surgery and blood was collected for determi-
nation of hematocrit, serum nitrate and sodium, plasma osmolality
and proteins, and plasma AVP measurements. The peritoneal exudate
was carefully collected for evaluating neutrophil migration into the
peritoneal cavity.
2.3. Cecal ligation and puncture (CLP)
Severe sepsis was induced by CLP, as previously described (Corrêa
et al., 2007; Pancoto et al., 2008; Athayde et al., 2009; Oliveira-Pelegrin
et al., 2009). Brieﬂy, ratswere anesthetizedwith 2, 2, 2-tribromoethanol
(Acros Organics, Geel, Belgium, 250 mg/kg i.p.). Under sterile surgical
conditions, a 2 cm midline incision was made on the ventral surface of
the abdomen, and the cecum was exposed and ligated below the
ileocecal junction without causing bowel obstruction. The cecum was
punctured 10 times with a 16-gage needle, and fecal contents were
allowed to spill into the peritoneum. The cecumwas repositioned in the
abdomen, and the peritoneal wall and skin incisions were closed. Sham
animals underwent an identical laparotomy, but did not undergo
ligation and puncture and served as controls. All animals received a
subcutaneous injection of saline (20 ml/kg body weight) immediately
after the surgery. The animals were allowed to recover in their cages
with free access to food and water.
2.4. Neutrophil migration into the peritoneal cavity
Neutrophil migration was assessed 4 h after CLP. The animals were
killed and the cells present in the peritoneal cavity were harvested by
introducing 15 ml of phosphate-buffered saline (PBS). Total counts
were performedwith Turk solution in a Neubauer chamber. Differential
cell counts were obtained using a cytocentrifuge (Cytospin 3, Shandon
Southern Products Ltd., Cheshire, UK) and staining with Panotico
(Laborclin LTDA, Pinhais Parana, Brazil). The results were expressed as
the number of neutrophils per ml of peritoneal exudate.
2.5. Determination of hematocrit, serum nitrate and sodium, plasma
osmolality and protein
Hematocritwasmeasured by centrifugation, serumsodiumbyﬂame
photometry (Micronal, São Paulo, Brazil), and plasma osmolality by
freezing-point depression (Precision System, Inc., Natick, MA, USA).
Plasma protein was determined by a Bradford colorimetric assay in a
Microplate reader (Bio-Rad Laboratories, Hercules, CA, USA), and nitrate
was quantiﬁed by chemoluminescence system (Sievers 280 NOA,
Sievers, Boulder, CO, USA).
2.6. Radioimmunoassay (RIA) for AVP
A RIA for AVPwas performed as previously described (Corrêa et al.,
2007). Brieﬂy, plasma samples (1.0 ml) were extracted using the
acetone/petroleum ether method, lyophilized and stored at −70 °C
until analysis. Standard reagents and incubation protocols were used
Fig. 2. Effect of intraperitoneal administration of MK-886 on neutrophil migration into
the peritoneal cavity (left panel) 4 h after CLP. The results are expressed as means±
SEM from 4 rats in each group.
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commercial antiserum (Peninsula Laboratories) at a ﬁnal dilution of
1:20,000. The antiserum is speciﬁc and shows essentially no cross-
reactivity with other known peptides. The buffer used composed of
Na2HPO4 (0.062 M) and Na2EDTA (0.013 M) supplemented with 0.5%
BSA, pH 7.5. For peptide labeling, 125I was purchased from a
commercial supplier (Amersham). A non-equilibrium assay was
used with an incubation volume of 500 μl and an incubation time of
4 days at 4 °C. Bound hormone was separated from unbound by a
secondary antibody produced in the laboratory of José Antunes-
Rodrigues and Lucila L.K. Elias where the RIA was performed. The
minimum detection limit was 0.9 pg/ml and the coefﬁcients of inter-
and intra-assay variations were 11% and 7%, respectively.
2.7. Data analysis
Survival rate was expressed as percentage, and a Log-rank (Mantel–
Cox) testwasused to determinedifferences in survival curves. The other
data are reported as mean±S.E.M. Statistical analyses were performed
by two-way analysis of variance (ANOVA) and a post hoc Tukey test.
Values of Pb0.05were considered statistically signiﬁcant. RIA datawere
analyzed by logit transformation of the raw data.
3. Results
3.1. Effects of MK-886 on survival rate
The survival rate in the animals submitted to CLP was 45% in the
ﬁrst day and 20% in the second and third day after surgery. Overall, the
injection of MK-886 did not signiﬁcantly alter survival (Fig. 1). In the
sham groups (sham+DMSO 5% or sham+MK-886), all rats survived
for 3 days after surgery (data not shown).
3.2. Effects of MK-886 on neutrophil migration
Concerning neutrophil migration into the peritoneal cavity we did
not detect any alteration in this parameter at the 4 h time point,
independent of MK-886 pretreatment or not. The neutrophil measure-
ment is indicative that the degree of sepsis was similar in the MK-886
treated and untreated CLP rats (Fig. 2).
3.3. Effects of MK-886 on hematocrit, serum sodium and nitrate, plasma
protein and osmolality
In the CLP group we observed at 4 h an increase in hematocrit
followed by a return to basal levels at 24 h after surgery (Table 1).Fig. 1. Effect of intraperitoneal administration of MK-886 on survival rate. Number of
animals in parentheses.Plasma protein levels of the CLP group were decreased at 4 and 24 h
after surgery. Concerning serum sodium and plasma osmolality we
observed minor alterations during sepsis. Pretreatment with MK-886
did not substantially affect the changes observed in these parameters.
3.4. Effects of MK-886 on serum nitrate
We observed an increase on serum nitrate at 4 and 24 h after CLP.
Pretreatment with MK-886 seemed to abolish the CLP-induced NO
increase seen at 4 h in a dose-dependent manner, but this was not
validated through statistical analysis (Fig. 3).
3.5. Effects of MK-886 in the plasma AVP levels
Sepsis induced by CLP, induced a signiﬁcant increase in plasma
AVP levels at 4 h after surgery. At 24 h the concentrations had
dropped to basal. Pretreatment with MK-886 in the doses of 1.0 and
2.0 mg/kg attenuated the release of the hormone. The dose of 4.0 mg/
kg of MK-886 completely abolished this hormonal response in the
early phase of sepsis (Fig. 4).
4. Discussion
The CLP experimental model was chosen because it best re-
produces the complex immunopathology of sepsis and closely
resembles the clinical situation of peritonitis due to mixed intestinal
microbiota (Echtenacher et al., 2001; Freise et al., 2001; Rios-Santos
et al., 2003; Nemzek et al., 2004).
All our CLP animals developed the clinical signs of sepsis, including
lethargy, piloerection and diarrhea, whereas sham animals remained
active in their cages. The survival rate was lower in the CLP animals
compared with sham rats, and no survival advantage was afforded by
the LTs synthesis inhibitor. In our experiments, MK-886 also did not
modify neutrophilmigration into the peritoneal cavity in rats submitted
to CLP. These results are in agreement with experiments done in lethal-
CLP (puncturing 14 times with a 21-gage needle) (Rios-Santos et al.,
2003) and studies that also did not reveal any alteration in survival rate
in LPS-induced sepsis (Azab and Kaplanski, 2004).
In the present study, we set the focus on the role of LTs in the
modulation of AVP release during experimental sepsis. Additionally
we asked whether this modulation could be through NO production
because the LTs seem to affect the production of this mediator
(Wilson et al., 2001; Knigge et al., 2003; Won et al., 2005). During the
initial phase of sepsis, CLP produced a signiﬁcant increase in plasma
AVP levels at 4 h, which returned to basal ones at 24 h, as shown in
previous studies (Pancoto et al., 2008; Athayde et al., 2009).
Intraperitoneal injection of MK-886, a LTs synthesis inhibitor,
Table 1
Effect of intraperitoneal administration of MK-886 on hematocrit, plasma protein, serum sodium and osmolality.
DMSO 5% MK-886 (1 mg/kg) MK-886 (2 mg/kg) MK-886 (4 mg/kg)
Sham CLP Sham CLP Sham CLP Sham CLP
Hematocrit (%)
0 43.9±1.0 46.5±0.8 44.3±0.5 44.2±1.3 44.8±0.8 44.1±0.8 44.7±1.0 44.7±1.0
4 45.7±1.8 56.3±1.3a 45.5±0.8 52.4±2.3a 47.4±1.4 53.5±0.9a 47.1±1.2 54.1±1.7a
24 43.4±1.4 46.7±1.0 43.6±1.8 47.6±1.1 44.4±0.5 46.4±1.5 44.4±0.8 46.7±2.0
Protein (g/dl)
0 11.4±0.4 11.4±0.3 10.1±0.6 9.7±0.3 11.2±0.1 10.9±0.3 11.4±0.2 10.7±0.4
4 8.4±0.9a 8.4±0.4b 10.0±0.5 9.4±0.7 9.4±0.5 7.6±0.6b,c 8.8±0.5a 8.4±0.4
24 10.7±0.5 8.1±0.5b,c 10.5±0.4 8.2±0.8c 9.9±0.2 7.4±0.0b,c 11.4±0.4 7.9±0.5b,c
Sodium (meq/kg)
0 136.0±1.8 140.4±1.4 137.8±1.9 142.3±1.1 140.6±0.8 142.8±1.2 141.6±1.0 141.4±1.2
4 140.8±1.1 141.0±1.8 140.2±2.2 138.8±1.5 139.0±1.5 135.8±1.3b 140.8±1.1 136.8±1.8
24 136.6±1.4 135.6±1.3a 139.5±0.5 135.3±1.7b 141.8±1.2 139.0±1.8 139.6±1.4 138.2±1.9
Osmolality (mOsm/kg)
0 281.7±2.8 284.0±2.5 279.5±3.0 277.0±3.0 291.4±3.3 285.7±4.5 288.2±2.2 288.7±3.0
4 270.1±2.7b 274.6±2.2b 278.8±4.4 277.5±2.4 276.2±2.1b 271.0±3.2b 274.0±2.4b 271.5±1.3b
24 274.3±3.5b 266.6±5.2b 265.2±3.9a 258.8±3.4a 274.0±2.1b 265.0±3.4b 277.9±1.4b 263.7±3.1b
Measurements are expressed as mean±SEM for each group comprising 5–10 animals. CLP, cecal ligation and puncture.
a Pb0.05 compared to 0 and 4 h within the group.
b Pb0.05 compared to 0 h within the group.
c Pb0.05 compared to the sham group.
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We hypothesize that its effect is independent of NO production,
because though the i.p. injection of MK-886 seems to prevent the
increase in nitrate production that usually occurs at 4 h after CLP,
overall there was no signiﬁcant difference between the groups pre-
treated or not with the drug.
Increase in serum sodium levels and osmolality are strong stimuli
for AVP release. We herein observed a signiﬁcant reduction in sodium
and osmolality at 4 and 24 h after CLP surgery. In previous studies we
observed a progressive increase in water intake at 4 h after CLP but no
alteration in diuresis (Corrêa et al., 2007; Oliveira-Pelegrin et al.,
2009), indicating a dilution of the body ﬂuid and consequent
reduction in serum sodium and osmolality. However, none of these
parameters were altered by pretreatment with MK-886.
Hypovolemia that usually occurs during sepsis may also contribute
to the observed AVP release (Parrillo, 1993). Accordingly we could see
an increase in hematocrit at 4 h of sepsis coinciding with the increase
in plasma AVP levels and in some time points with a drop in plasma
protein. However, the pretreatment with MK-886 did not substan-Fig. 3. Effect of intraperitoneal administration of MK-886 on serum nitrate. The results
are expressed as means±SEM. §Pb0.05 compared to 0 h within the group. ⁎Pb0.001
compared to 0 and 4 h within the group. n=6–10 each group.tially change plasma protein and hematocrit levels. Hypovolemia can
be due to the liberation of inﬂammatory mediators that can cause
damage to endothelial cell, with consequent capillary leakage and
major loss of ﬂuid and protein into the interstitial space (Parrillo,
1993; Andrew et al., 2000; Fishel et al., 2003; Benjamim et al., 2005).
In a previous study we already observed a decrease in plasma protein
concentration after CLP surgery that was attenuated following
pretreatment with aminoguanidine, an iNOS inhibitor (Corrêa et al.,
2007).
Several explanations are possible for the effect of MK-886 on the
liberation of AVP during the initial phase of the sepsis. An attenuation
of the increase in the plasma concentration of this hormone was also
observed when we systemically inhibited NO production by admin-
istration of aminoguanidine (Corrêa et al., 2007). We concluded that
the decrease in blood pressure due to the liberation of NO and other
mediators can be at least partially responsible for the AVP release
observed in the early phase of sepsis. Similarly, the fact that i.c.v
injection of MK-886 attenuated and even abolished the increase in theFig. 4. Effect of intraperitoneal administration of MK-886 on plasma vasopressin levels.
The results are expressed as means±SEM; §Pb0.05 compared to 4 h within the group;
⁎Pb0.05 compared to CLP+DMSO group; #Pb0.05 compared to CLP+1 mg/kg group;
†Pb0.05 compared to CLP+2 mg/kg group. n=6–12 each group.
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increase or normalization of the blood pressure (Benjamim et al., 2005;
Athayde et al., 2009). Reestablishment of blood pressure was also seen
in mice pretreated with MK-571 a cys-LTs receptor antagonist before
being submitted to CLP (Benjamim et al., 2005).
It is possible that the i.p. injection of MK-886 acted centrally
because LTC4 synthase, but not LTA4 hydrolase, is selectively localized
in vasopressinergic neurons of the hypothalamus (Shimada et al.,
2005). Moreover together with its vehicle it can cross the blood–brain
barrier (Iwen and Miller, 1986), and thus be directly responsible for
the diminished AVP release. Previous studies showed that i.p injection
of MK-886 attenuated the increase in LPS-induced production of
hypothalamic cys-LTs (Paul et al., 1999; Azab and Kaplanski, 2004),
suggesting that the drug can reach the central nervous system.
Furthermore, we could previously show that the i.c.v injection of MK-
886 blocked the increase in hypothalamic LTC4 synthase observed 4 h
after CLP. This effect happened at the same time as the attenuated
increase in plasma AVP levels. These results, therefore, indicate a role
of central LTs in the liberation of AVP. The present study now showed
that the MK-886 administered intraperitoneally is also able to
decrease the vasopressin release in a dose–response manner during
sepsis, implicating a role for leukotrienes. Additionally this effect
seems to be independent of NO production.Acknowledgments
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